FDA-Approved aBLAs

# Biosimilar Applicant Reference Product aBLA Approval US Launch? Pending BPCIA Litigation?
1 ZARXIO® (filgrastim-sndz) Sandoz NEUPOGEN® Mar. 6, 2015 Sept. 3, 2015 Amgen v. Sandoz
2 INFLECTRA® (infliximab-dyyb) Celltrion REMICADE® Apr. 5, 2016 Late 2016 Janssen v. Celltrion
3 ERELZI® (etanercept-szzs) Sandoz ENBREL® Aug. 30, 2016 No Immunex v. Sandoz
4 AMJEVITA® (adalimumab-atto) Amgen HUMIRA® Sept. 23, 2016 No AbbVie v. Amgen
5 RENFLEXIS® (infliximab-abda) Samsung Bioepis REMICADE® Apr. 21, 2017 No None

Last updated: May 3, 2017

Download PDF